Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Deferred Revenue: 2017-2025

Historic Current Deferred Revenue for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $105.0 million.

  • Arcus Biosciences' Current Deferred Revenue fell 73.35% to $105.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.0 million, marking a year-over-year decrease of 73.35%. This contributed to the annual value of $319.0 million for FY2024, which is 19.85% down from last year.
  • Per Arcus Biosciences' latest filing, its Current Deferred Revenue stood at $105.0 million for Q3 2025, which was down 19.85% from $131.0 million recorded in Q2 2025.
  • Arcus Biosciences' Current Deferred Revenue's 5-year high stood at $429.0 million during Q3 2023, with a 5-year trough of $35.0 million in Q2 2023.
  • Over the past 3 years, Arcus Biosciences' median Current Deferred Revenue value was $319.0 million (recorded in 2024), while the average stood at $262.9 million.
  • As far as peak fluctuations go, Arcus Biosciences' Current Deferred Revenue surged by 965.30% in 2021, and later plummeted by 73.35% in 2025.
  • Over the past 5 years, Arcus Biosciences' Current Deferred Revenue (Quarterly) stood at $102.0 million in 2021, then decreased by 4.90% to $97.0 million in 2022, then skyrocketed by 310.31% to $398.0 million in 2023, then decreased by 19.85% to $319.0 million in 2024, then slumped by 73.35% to $105.0 million in 2025.
  • Its last three reported values are $105.0 million in Q3 2025, $131.0 million for Q2 2025, and $291.0 million during Q1 2025.